Literature DB >> 7749984

Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA).

J L Riley1, S D Westerheide, J A Price, J A Brown, J M Boss.   

Abstract

CIITA, a gene that can complement a transcriptional mutation of the major histocompatibility complex (MHC) class II genes, was tested for its ability to function as a coactivator, CIITA cDNA clones isolated showed alternative RNA splicing, but only one splice site combination was able to restore class II MHC gene expression. DNA-mediated transfection experiments showed that CIITA directs its activity through the X box element; the presence of CIITA leads to the formation of a higher order complex at the X box region; and CIITA contains a potent activation domain. These findings support the hypothesis that CIITA directly interacts with the MHC class II-specific transcription factors and is required for expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7749984     DOI: 10.1016/1074-7613(95)90033-0

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  50 in total

1.  Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains.

Authors:  M W Linhoff; J A Harton; D E Cressman; B K Martin; J P Ting
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

Review 2.  The bare lymphocyte syndrome: molecular clues to the transcriptional regulation of major histocompatibility complex class II genes.

Authors:  A DeSandro; U M Nagarajan; J M Boss
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

3.  CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.

Authors:  K Masternak; A Muhlethaler-Mottet; J Villard; M Zufferey; V Steimle; W Reith
Journal:  Genes Dev       Date:  2000-05-01       Impact factor: 11.361

Review 4.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

5.  Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines.

Authors:  G Li; J A Harton; X Zhu; J P Ting
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

6.  CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.

Authors:  S B Hake; K Masternak; C Kammerbauer; C Janzen; W Reith; V Steimle
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

7.  Associations and interactions between bare lymphocyte syndrome factors.

Authors:  A M DeSandro; U M Nagarajan; J M Boss
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 8.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

9.  Novel functions for TAF7, a regulator of TAF1-independent transcription.

Authors:  Ballachanda N Devaiah; Hanxin Lu; Anne Gegonne; Zeynep Sercan; Hongen Zhang; Robert J Clifford; Maxwell P Lee; Dinah S Singer
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

10.  Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS.

Authors:  Monica Vaccari; Rabih Halwani; L Jean Patterson; Adriano Boasso; Jennifer Beal; Elzbieta Tryniszewska; Anna Hryniewicz; David Venzon; Elias K Haddad; Mohamed El-Far; Margherita Rosati; George N Pavlakis; Barbara K Felber; Saleh Al-Muhsen; Marjorie Robert-Guroff; Rafick-Pierre Sekaly; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.